Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The claims correctly identify several discontinuation symptoms and the label's preference for gradual dose reduction. However, most specific duration, prevalence, risk-factor, and self-care claims are not established by the supplied label information, and the fixed taper schedules are not label recommendations.
Category Scores
Accurate Statements
Discontinuation can involve dizziness, nausea, irritability, electric-shock-like sensory disturbances, insomnia, and anxiety.
Section 5.3 lists these among reported discontinuation symptoms.
Gradual dose reduction is recommended rather than abrupt discontinuation whenever possible.
Sections 2.5 and 5.3 support gradual reduction and describe discontinuation symptoms, particularly with abrupt discontinuation.
Suicidal thoughts during this period warrant attention and monitoring.
Section 5.1 advises monitoring for clinical worsening and suicidal thoughts or behaviors, though it does not frame this as a withdrawal-specific threshold.
Unsupported Statements
Withdrawal typically lasts 1–3 weeks, peaks in the first week, resolves within two weeks or by week four, or follows the other stated recovery timelines.
The label does not specify typical duration, peak timing, or recovery timelines.
Withdrawal lasts longer or is more severe based on dose, duration of use, age, genetics, metabolism, co-existing anxiety, or faster metabolism; or that stated percentages experience protracted withdrawal.
The label does not establish these predictors, mechanisms, or prevalence estimates.
A 4–8-week taper or a reduction of 5 mg every 1–2 weeks is a recommended schedule.
The label recommends gradual reduction but does not prescribe either fixed schedule.
Fish oil, hydration, exercise, or caffeine changes ease or worsen withdrawal; alcohol worsens withdrawal.
The supplied label information does not recommend these measures or state these withdrawal-specific effects.
Withdrawal is caused by serotonin imbalance or rebound effects, can mimic relapse, and professional monitoring can prevent misdiagnosis.
These claims are not established by the supplied label information.
Symptoms lasting over three weeks, severe depression, or seizures are withdrawal-specific thresholds for seeking medical help.
The label does not specify these thresholds. It does advise monitoring for clinical worsening and suicidal thoughts or behaviors, and lists seizures among reported discontinuation-related events.
Fatigue is a listed discontinuation symptom.
The label lists lethargy, but does not specifically state fatigue.
Low-dose reinstatement is recommended for severe or protracted withdrawal.
The label says to consider resuming the previously prescribed dose if symptoms are intolerable, then reducing more gradually; it does not specifically recommend restarting at a low dose or address protracted withdrawal.
Contradictions
Important Omissions
The label's advice for intolerable symptoms after dose reduction or discontinuation is to consider resuming the previously prescribed dose and then reducing it more gradually; the claims instead specify restarting at a low dose.
Importance:
Moderate
The label does not provide the stated timelines or fixed taper schedules; this limitation should be made clear when discussing them.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The label-supported symptom information and gradual-reduction advice are useful, but precise taper schedules and unsupported claims about duration, risk factors, and remedies could be mistaken for label recommendations. The label advises gradual reduction when possible and provides guidance for intolerable symptoms.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Numerous specific timelines, prevalence estimates, predictors, and management claims are not supported by the supplied label information; the fixed taper schedules are not label recommendations.
Suggested Improvement
Keep the listed label-supported discontinuation symptoms and gradual-reduction advice, describe the label's guidance for intolerable symptoms accurately, and clearly identify any timelines or other management claims as not specified in the label.